Search
Mesoblast Ltd
MESOAdd to Watchlist
15.750USD
+0.250+1.61%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
2.02BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-22The current earnings forecast score of Mesoblast Ltd is 8.00, ranking 164 out of 389 in the Biotechnology & Medical Research industry. The average price target is 35.00, with a high of 35.00 and a low of 35.00.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
34.667
Target Price
+141.24%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Mesoblast Ltd
MESO
3
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Mesoblast Ltd's price target?
Analysts forecast that Mesoblast Ltd's price target is USD 35.00, with the highest forecast at USD 35.00 and the lowest forecast at USD 35.00.
What is the analyst rating for Mesoblast Ltd?
Based on the ratings of Mesoblast Ltd's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
